

## Supplement

### Estimating prevalence of subjective cognitive decline in and across international cohort studies of ageing:

#### A COSMIC study

#### INDEX

1. Tables.....	2
Table e-1. Key references for contributing studies .....	2
Table e-2. Dementia diagnosis at baseline .....	3
Table e-3. Selected items forming a bridging item to indicate a self-experienced decline in cognitive capacity across studies. ....	4
Table e-4. Availability of additional items for a self-experienced decline in cognitive capacity.....	5
Table e-5. Instruments used for assessing instrumental activities of daily living (IADL) .....	7
Table e-6. Harmonization protocol for major depressive symptomatology .....	8
Table e-7. Harmonization protocol for major anxiety symptomatology .....	9
Table e-8. Study-based prevalence estimates for subjective cognitive decline (SCD; right column) and cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to quantitative harmonization based on studies with multiple items.....	10
2. References .....	11

## 1. Tables

<b>Table e-1. Key references for contributing studies.</b>	
<b>Study</b>	<b>Key reference</b>
Atma Jaya Cognitive & Aging Research (ActiveAging)	Turana et al. 2014 <sup>1</sup>
Cognitive Function & Ageing Studies (CFAS)	Brayne, McCracken & Matthews 2006 <sup>2</sup>
Einstein Aging Study USA (EAS)	Katz et al. 2012 <sup>3</sup>
Epidemiology of dementia in Central Africa (EPIDEMCA)	Guerchet et al. 2014 <sup>4</sup>
Etude Santé Psychologique et Traitement (ESPRIT)	Ritchie, Carrière, Ritchie, Berr, Artero & Ancelin 2010 <sup>5</sup>
Invecchiamento Cerebrale in Abbiategrasso (Invece.Ab)	Guaita et al. 2013 <sup>6</sup>
Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD)	Han et al. 2018 <sup>7</sup>
Leipzig Longitudinal Study of the Aged (LEILA75+)	Riedel-Heller, Schork, Matschinger & Angermeyer 2000 <sup>8</sup>
Long-term Research Grant Scheme - Towards Useful Aging (LRGS-TUA)	Shahar et al. 2015 <sup>9</sup>
Maastricht Aging Study (MAAS)	Jolles, van Boxtel, Ponds, Metsmakers & Houx 1998 <sup>10</sup>
Monongahela Valley Independent Elders Survey (MoVIES)	Ganguli, Mendelsohn, Lytle & Dodge 1998 <sup>11</sup>
Personality and Total Health Through Life Project (PATH)	Anstey et al. 2012 <sup>12</sup>
Sasaguri Genkimon Study (SGS)	Narazaki, Nofuji, Honda, Matsuo, Yonemoto, Kumagai 2013 <sup>13</sup>
Singapore Longitudinal Ageing Studies II (SLASII)	Feng et al. 2010 <sup>14</sup>
Sydney Memory and Ageing Study (SydneyMAS)	Sachdev et al. 2010 <sup>15</sup>
Zaragoza Dementia Depression Project (ZARADEMP)	Lobo et al. 2005 <sup>16</sup>

<b>Table e-2. Dementia diagnosis at baseline.</b>	
<b>Study</b>	<b>Dementia criteria</b>
ActiveAgeing	DSM-IV <sup>17</sup>
CFAS	AGECAT <sup>18</sup> ; organicity level of O3
EAS	DSM-IV
EPIDEMCA	DSM-IV
ESPRIT	Standardized interview by a neurologist incorporating cognitive testing, with diagnoses validated by an independent panel of expert neurologists.
Invece.Ab	DSM-IV
KLOSCAD	DSM-IV
LEILA75+	DSM-IV
LRGS-TUA	N/A
MAAS	N/A
MoVIES	CDR <sup>19</sup> $\geq$ 1
PATH	DSM-IV
SGS	Self-reported medical history
SLAS II	DSM-IV
SydneyMAS	DSM-IV
ZARADEMP	DSM-IV

Abbreviations: AGECAT: Automated Geriatric Examination for Computer Assisted Taxonomy), CDR = Clinical Dementia Rating; DSM - Diagnostic and Statistical Manual of Mental Disorders; N/A = Not applicable/dementia excluded per study design

**Table e-3. Selected items forming a bridging item to indicate a self-experienced decline in cognitive capacity across studies.**

Study	Selected item*	Coding**	Instrument	Item properties
ActiveAgeing	Do you feel you have more problems with your memory than most?	1 = yes, 2 = no	GDS <sup>20</sup>	Memory; relation to others
CFAS	Have you ever had any difficulty with your memory? Is that a problem for you?	0 = no, 1 = yes: 0 = no, 1 = yes, moderate, 2 = yes, severe	NSQ	Memory; relation to time: ever
EAS	Compared with one year ago, do you have trouble remembering things more often, less often or about the same?	1 = more often, 2 = less often, 3 = about the same	NSQ	Memory; relation to time: 1 year
EPIDEMCA	GMS - Subjective difficulty, i.e., implies memory impairment	0 = no, 1 = yes	NSQ	Memory
ESPRIT	Are you usually experiencing any of the following symptoms: Forgetful in everyday activities?	0 = no, 1 = yes	NSQ	Memory
Invece.Ab	Do you think to have memory problems?	0 = no, 1 = yes	NSQ	Memory
KLOSCAD	Do you think that you have a memory problem?	0 = no, 1 = yes	SMCQ <sup>21,22</sup>	Memory
LEILA75+	Do have problems with your memory?	0 = no, 1 = yes	NSQ	Memory
LRGS-TUA	Are you having problems with your memory currently?	0 = no, 1 = yes	GDS	Memory
MAAS	Have cognitive failures increased during past 5 years?	0 = not at all, 1 = very little, 2 = somewhat, 3 = much, 4 = very much	NSQ	Cognition, relation to time: 5 years
MoVIES	In general, how good do you feel your memory is for a person your age?	1 = excellent, 2 = good, 3 = fair, 4 = poor	NSQ	Memory, relation to age
PATH	Remembering things that have happened recently	1 = much improved, 2 = a bit improved, 3 = not much change, 4 = a bit worse, 5 = much worse	IQCODE <sup>22</sup>	Memory: relation to time: recent; self-administered
SGS	Are you sometimes unable to recall date of today/a day?	1 = yes, 2 = no	NSQ	Memory
SLAS II	Overall, how would you rate your memory or other mental abilities as compared to earlier period of your life (more than one year ago)?	1 = much better, 2 = a bit better, 3 = a bit worse, 5 = much worse	NSQ	Memory, cognition: relation to time: >1 year
SydneyMAS	Have you noticed difficulties with your memory?	1 = no, 2 = yes	NSQ	Memory
ZARADEMP	Have you had any difficulty with your memory?	0 = no, 1 = yes	NSQ	Memory

Abbreviations: GDS = Geriatric Depression Scale; NSQ = No specified instrument/self-formulated questions; IQCODE = Informant Questionnaire for Cognitive Decline in the Elderly; SMCQ = Subjective Memory Complaints Questionnaire

\*measurement approach: population-based; respondent category: self-report; administration mode: interview

\*\*for harmonization, categories were collapsed/dichotomized and/or recoded, if necessary, into 0 = no (absence of a self-experienced decline in cognitive capacity) and 1 = yes (presence of a self-experienced decline in cognitive capacity). Any indication of a self-experienced decline in cognitive capacity was categorized as “1”.





**Table e-5. Instruments used for assessing instrumental activities of daily living (IADL).**

<b>Study</b>	<b>IADL Instruments</b>
ActiveAgeing	Lawton & Brody IADL Scale <sup>23</sup>
CFAS	Modified Townshend Disability Scale <sup>24</sup>
EAS	Lawton & Brody IADL Scale
EPIDEMCA	Adapted Lawton & Brody IADL Scale
ESPRIT	Lawton & Brody IADL Scale
Invece.Ab	Lawton & Brody IADL Scale
KLOSCAD	Disability Assessment of Dementia (DAD) <sup>25</sup>
LEILA75+	SIDAM-A structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10, DSM-III-R and DSM-IV (SIDAM-B) <sup>26</sup>
LRGS-TUA	Lawton & Brody IADL Scale
MAAS	Lawton & Brody IADL Scale
MoVIES	Older Americans' Resources and Services Multidimensional Functional Assessment Questionnaire Center Instrument (OMFAQ) <sup>27</sup>
PATH	Lawton & Brody IADL Scale
SGS	Five-item scale for instrumental self-maintenance of the Tokyo Metropolitan Institute of Gerontology Index of Competence (TMIG) <sup>28</sup>
SLAS II	Lawton & Brody IADL Scale
SydneyMAS	Bayer ADL Scale <sup>29</sup>
ZARADEMP	Lawton & Brody IADL Scale

**Table e-6. Harmonization protocol for major depressive symptomatology.**

<b>Study</b>	<b>Current*</b>	<b>History*</b>
ActiveAgeing	GDS $\geq$ 11	N/A
CFAS	GMS-AGECAT rating of subcase or clinical case	Diagnosis of depression or manic depression
EAS	GDS $\geq$ 11	N/A
EPIDEMCA	GMS-AGECAT rating of subcase or clinical case	N/A
ESPRIT	1. Current major depressive episode (MINI neuropsychiatric exam <sup>30</sup> ) 2. CES-D <sup>31</sup> score $\geq$ 24	History of major depressive episode (MINI neuropsychiatric exam)
Invece.Ab	1. Use of anti-depressants 2. GDS score $\geq$ 11 3. Criteria-based diagnosis by physician/ psychologist (including medication, GDS score and CES-D items)	N/A
KLOSCAD	1. Diagnosis with status as “following-up” or “under treatment” 2. NPI <sup>32</sup> part D 3. Clinical diagnosis of major depressive disorder 4. Korean GDS score $\geq$ 16	1. History of depression
LEILA75+	1. DSM-IV criteria based on structured clinical interview 2. CES-D score $\geq$ 24	Self-reported history
LRGS-TUA	GDS $\geq$ 11	N/A
MAAS	SCL-90 <sup>33</sup> Depression subscale	N/A
MoVIES	mCES-D $\geq$ 5	N/A
PATH	1. GADS <sup>34</sup> $\geq$ 6 2. Use of anti-depressants	Self-reported history and doctor seen
SGS	K6 <sup>35</sup> $\geq$ 5 (combined with anxiety)	N/A
SLAS II	1. GDS $\geq$ 11 2. Major depressive disorder by SCID	History of depression by antidepressant and report
SydneyMAS	1. GDS $\geq$ 11 2. Use of medication/treatment with GP/psychiatrist/psychologist/in hospital	Depression ever diagnosed
ZARADEMP	GMS-AGECAT rating of subcase or clinical case	N/A

Abbreviations: CES-D = Centre for Epidemiological Studies - Depression Scale; CIRS = Cumulative Illness Rating Scale; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders (4th edition); GADS = Goldberg Anxiety and Depression Scale depression score; GDS = Geriatric Depression Scale; GMS-AGECAT = Geriatric Mental State - Automated Geriatric Examination for Computer Assisted Taxonomy; GP = general practitioner; ICD-10 = International Classification of Diseases (10th revision); mCES-D = modified Centre for Epidemiological Studies - Depression Scale; K6 = Kessler Psychological Distress Scale; MINI = Mini International Neuropsychiatric Interview; N/A = not available; NPI = Neuropsychiatric Inventory; SCID = Structured Clinical Interview for DSM-IV; SCL-90 = Symptom Checklist

\*for studies with more than one measure, meeting criteria for either was sufficient.



**Table e-7. Harmonization protocol for major anxiety symptomatology.**

Study	Criteria
ActiveAgeing	N/A
CFAS	GMS-AGECAT confidence/severity rating $\geq 3$
EAS	BAI <sup>36</sup> $\geq 19$
EPIDEMCA	GMS-AGECAT probable Anxiety
ESPRIT	MINI neuropsychiatric exam diagnosis of current anxiety or generalized anxiety disorder
Invece.Ab	Use of anxiolytics
KLOSCAD	1. Diagnosis with status “following-up” or “under treatment” 2. NPI part E [scale score=anxiety x severity]
LEILA75+	N/A
LRGS-TUA	N/A
MAAS	SCL-90 Anxiety Subscale
MoVIES	N/A
PATH	1. GADS, anxiety score $\geq 5$ 2. Anxiety medications taken
SGS	K6, anxiety score $\geq 5$
SLAS II	self-reported history of anxiety, or presence of anxiety symptoms based on NPI
SydneyMAS	GADS, anxiety score $\geq 5$
ZARADEMP	GMS-AGECAT diagnosis

Abbreviation: BAI = Beck Anxiety Scale; GADS = Goldberg Anxiety and Depression Scale depression score; GMS-AGECAT = Geriatric Mental State-Automated Geriatric Examination for Computer Assisted Taxonomy; K6 = Kessler Psychological Distress Scale; MINI = Mini International Neuropsychiatric Interview; N/A = not available; NPI = Neuropsychiatric Inventory; SCL-90 = Symptom Checklist

**Table e-8. Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; right column) and cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to quantitative harmonization based on studies with additional items for a self-experienced decline in cognitive capacity.**

Study	SCD operationalization criteria			
	Criterion 1 Endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment	+ Criterion 2 Intact functional ability	+ Criterion 3 No major depression	+ Criterion 4 No anxiety disorder
	% (95% CI)			
CFAS	23.53 (22.13-24.93)	21.62 (20.22-23.01)	17.83 (16.64-19.02)	9.40 (8.44-10.36)
EAS	50.33 (44.88-55.78)	45.84 (40.61-51.06)	39.05 (34.67-44.33)	25.64 (18.76-32.52)
EPIDEMCA	57.71 (55.58-59.85)	54.35 (52.13-56.58)	31.38 (29.21-33.55)	28.43 (26.42-30.44)
ESPRIT	31.97 (30.01-33.93)	29.49 (27.58-31.41)	24.55 (22.74-26.36)	18.90 (17.34-20.47)
KLOSCAD	55.59 (54.16-57.02)	50.61 (49.15-52.08)	36.00 (34.60-37.41)	35.84 (34.52-37.16)
MoVIES	30.01 (27.61-32.54)	27.83 (25.41-30.24)	24.39 (22.06-26.71)	N/A
PATH	11.93 (10.71-13.14)	10.98 (9.80-12.16)	9.82 (8.69-10.95)	7.84 (6.78-8.90)
SLAS II	25.61 (23.48-27.74)	23.00 (20.94-25.06)	22.31 (20.28-24.35)	21.16 (19.32-23.01)
SydneyMAS	46.48 (44.36-48.60)	43.35 (41.09-45.61)	36.42 (34.08-38.77)	29.20 (26.94-31.47)
<b>Total*</b>	<b>36.52 (35.97-37.08)</b>	<b>33.73 (33.18-34.28)</b>	<b>27.02 (26.50-27.54)</b>	<b>26.07 (25.43-26.72)</b>

Abbreviations: 95% CI = 95% confidence interval; N/A = not available; \*unstandardized

## 2. e-References

1. Turana Y, Ranakusuma TAS, Purba JS, Amir N, Ahmad SA, Machfoed MH, et al. Enhancing Diagnostic Accuracy of aMCI in the Elderly: Combination of Olfactory Test, Pupillary Response Test, BDNF Plasma Level, and APOE Genotype. *Int J Alzheimers Dis* 2014;2014:9.
2. Brayne C, McCracken C, Matthews FE. Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). *Int J Epidemiol* 2006;35(5):1140-1145.
3. Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. *Alzheimer Dis Assoc Disord* 2012;26(4):335-343.
4. Guerchet M, Mbelesso P, Ndamba-Bandzouzi B, Pilleron S, Desormais I, Lacroix P, et al. Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre population-based study in rural and urban areas of the Central African Republic and the Republic of Congo. *Springerplus* 2014;3(1):338.
5. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin M-L. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ* 2010;341:c3885.
6. Guaita A, Colombo M, Vaccaro R, Fossi S, Vitali SF, Forloni G, et al. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. *BMC Geriatr* 2013;13:98.
7. Han JW, Kim TH, Kwak KP, Kim K, Kim BJ, Kim SG, et al. Overview of the Korean Longitudinal Study on Cognitive Aging and Dementia. *Psychiatry Investig*. 2018;15(8):767-774.
8. Riedel-Heller SG, Schork A, Matschinger H, Angermeyer MC. Recruitment Procedures and Their Impact on the Prevalence of Dementia. *Neuroepidemiology* 2000;19(3):130-140.
9. Shahar S, Omar A, Vanoh D, Hamid TA, Mukari SZ, Din NC, et al. Approaches in methodology for population-based longitudinal study on neuroprotective model for healthy longevity (TUA) among Malaysian Older Adults. *Aging Clin Exp Res* 2016;28(6):1089-1104.
10. Jolles J, van Boxtel MP, Ponds RW, Metsemakers JF, Houx PJ. The Maastricht aging study (MAAS). The longitudinal perspective of cognitive aging. *Tijdschr Gerontol Geriatr* 1998;29(3):120-129.
11. Ganguli M, Mendelsohn A, Lytle M, Dodge H. A follow-up comparison of study participants and refusers within a rural elderly population. *J Gerontol A Biol Sci Med Sci* 1998;53(6):M465-70.
12. Anstey KJ, Christensen H, Butterworth P, Eastel S, Mackinnon A, Jacomb T, et al. Cohort profile: the PATH through life project. *Int J Epidemiol* 2012;41(4):951-960.
13. Narazaki K, Nofuji Y, Honda T, Matsuo E, Yonemoto K, Kumagai S. Normative data for the montreal cognitive assessment in a Japanese community-dwelling older population. *Neuroepidemiology* 2013;40(1):23-29.
14. Feng L, Chong MS, Lim WS, Lee TS, Collinson SL, Yap P, Ng TP. Metabolic syndrome and amnesic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings. *J Alzheimers Dis* 2013;34(3):649-657.
15. Sachdev PS, Brodaty H, Reppermund S, Kochan NA, Trollor JN, Draper B, et al. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. *Int Psychogeriatr* 2010;22(8):1248-1264.
16. Lobo A, Saz P, Marcos G, D a JL, De-la-C amara C, Ventura T, et al. The ZARADEMP Project on the incidence, prevalence and risk factors of dementia (and depression) in the elderly community: II. Methods and first results. *Eur J Psychiatry* 2005;19:40-54.
17. *Diagnostic and statistical manual of mental disorders: DSM-IV*: Fourth edition. Washington, DC: American Psychiatric Association;1994.
18. Dewey ME, Copeland JRM. Computerized psychiatric diagnosis in the elderly: AGE-CAT. *J Microcomput Appl* 1986;9(2):135-140.
19. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr* 1997;9 Suppl1:173-176; discussion 177-178.
20. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. *Clin Gerontol* 1986;5(1-2):165-173.
21. Youn JC, Kim KW, Lee DY, Jhoo JH, Lee SB, Park JH, et al. Development of the Subjective Memory Complaints Questionnaire. *Dement Geriatr Cogn Disord* 2009;27(4):310-317.
22. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. *Psychol Med* 1989;19(4):1015-1022.
23. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living1. *Gerontologist* 1969;9(3\_Part\_1):179-186.

24. Townsend P. *Poverty in the United Kingdom: A survey of household resources and standards of living*. Repr. Harmondsworth: Penguin;1983.
25. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. *Am J Occup Ther* 1999;53(5):471-481.
26. Zaudig M, Mittelhammer J, Hiller W, et al. SIDAM—A structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. *Psychol Med* 1991;21(1):225-236.
27. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. *J Gerontol* 1981;36(4):428-434.
28. Koyano W, Shibata H, Nakazato K, Haga H, Suyama Y. Measurement of competence: reliability and validity of the TMIG Index of Competence. *Arch Gerontol Geriatr*. 1991;13(2):103-116.
29. Hindmarch I, Leffeld H, de Jongh P, Erzigkeit H. The Bayer activities of daily living scale (B-ADL). *Dement Geriatr Cogn Disord* 1998;9(Suppl. 2):20-26.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;59 Suppl 20:22-33;quiz 34-57.
31. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Appl Psychol Meas* 1977;1(3):385-401.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994;44(12):2308-2314.
33. Derogatis LR. *SCL 90 R Administration, Scoring and Procedures Manual II for the Revised Version and Other Instruments of the Psychopathology Rating Scale Series: Clinical Psychometric Research*;1986.
34. Goldberg DP, Bridges K, Duncan-Jones P, Grayson D. Dimensions of neuroses seen in primary-care settings. *Psychol Med* 1987;17(2):461-470.
35. Kessler RC, Andrews G, Colpe LJ, Hirpi E, Mroczek DK, Normand SL, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. *Psychol Med* 2002;32(6):959-976.
36. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *JCCP* 1988;56(6):893.